Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
Propanc Biopharma announced progress towards a pivotal Phase 1b First-In-Human clinical trial for its lead asset PRP targeting advanced cancer patients. The company executed a service agreement to validate pharmacokinetic assays and entered a multi-year research collaboration focused on anti-aging and cancer treatments with Spanish universities. Fi…